A recurrent somatic activating mutation in the nonreceptor tyrosine kinase JAK2 (JAK2V617F) occurs in the majority of patients with the myeloproliferative disorders polycythemia vera, essential thrombocythemia, myelofibrosis with myeloid metaplasia, and, less commonly, chronic myelomonocytic leukemia. We do not understand the basis for the specificity of the JAK2V617F mutation in clonal disorders of the myeloid, but not lymphoid, lineage, nor has the basis for the pleiotropic phenotype of JAK2V617F-associated myeloproliferative disorders been delineated. However, the presence of the identical mutation in patients with related, but clinicopathologically distinct, myeloid disorders suggests that interactions between the JAK2V617F kinase and other signaling molecules may influence the phenotype of hematopoietic progenitors expressing JAK2V617F. Here, we show that coexpression of the JAK2V617F mutant kinase with a homodimeric Type I cytokine receptor, the erythropoietin receptor (EpoR), the thrombopoietin receptor, or the granulocyte colony-stimulating-factor receptor, is necessary for transformation of hematopoietic cells to growthfactor independence and for hormone-independent activation of JAK-STAT signaling. Furthermore, EpoR mutations that impair erythropoietin-mediated JAK2 or STAT5 activation also impair transformation mediated by the JAK2V617F kinase, indicating that JAK2V617F requires a cytokine receptor scaffold for its transforming and signaling activities. Our results reveal the molecular basis for the prevalence of JAK2V617F in diseases of myeloid lineage cells that express these Type I cytokine receptors but not in lymphoid lineage cells that do not.
C
onstitutive activation of tyrosine kinases by chromosomal translocation (1), interstitial deletion (2), internal tandem duplication (3), or amino acid substitution (4) are frequent pathogenetic events in hematopoietic malignancies. These constitutively activated kinases are disengaged from normal regulatory mechanisms and activate signal-transduction pathways, including the STAT, RAS͞MAPK, and PI3K͞AKT pathways that confer proliferative and survival advantage to hematopoietic progenitors. For example, TEL-JAK2 is a chimeric tyrosine kinase that is expressed in hematopoietic malignancies as a consequence of the t (9, 12)(p24;p13) translocation (5, 6) . JAK2 is normally tightly associated with the cytosolic domain of a cytokine receptor and, after cytokine binding to the cognate receptor, becomes activated by transphosphorylation of a tyrosine residue in the activation loop. In contrast, TEL-JAK2 is localized to the cytosol and activates STAT5 without a requirement for cytokine stimulation or binding to a cytokine receptor (7) . Indeed, the TEL-JAK2 fusion lacks the conserved JH3 to JH7 domains that are required for JAK2 association with cytokine receptors (8) .
We and others recently reported an association between a somatic point mutation of the JAK2 tyrosine kinase (JAK2V617F) and the myeloproliferative diseases polycythemia vera, essential thrombocythemia, and myeloid metaplasia (9-13). Functional assays revealed that JAK2V617F transforms certain lines of hematopoietic cells that express the erythropoietin receptor (EpoR) to growth factor independence and induces constitutive phosphorylation of the STAT5 transcription factor (9, 11) . The specificity of the JAK2V617F mutation in clonal disorders of the myeloid, but not lymphoid, lineage and the pleiotropic phenotype of JAK2V617F-associated myeloproliferative disorders are not fully understood.
Here, we show that JAK2V617F functions differently from constitutively activated kinases, such as TEL-JAK2. In IL-3-dependent hematopoietic cell lines, the ability of JAK2V617F to induce cytokine-independent activation of the JAK2 and STAT5 pathways and transformation to cytokine independence requires the coexpression of homodimeric Type I cytokine receptors, such as EpoR, thrombopoietin receptor (TpoR), or granulocyte colony-stimulating-factor receptor (GCSFR). Further, a mutant EpoR that fails to bind JAK2 also fails to support JAK2V617F-mediated transformation and constitutive STAT5 activation. An EpoR mutant that lacks cytosolic tyrosines and is deficient in Epo-induced STAT5 activation supports cytokine-independent activation of JAK2V617F but is defective in supporting JAK2V617F-mediated STAT5 activation and cytokineindependent growth. Our results suggest that, unlike other constitutively activating kinase mutants previously identified, JAK2V617F depends on cognate cytokine receptors for both its activation and the activation of downstream signal-transduction proteins. This finding provides mechanistic insights into the prevalence of JAK2V617F in myeloproliferative diseases like essential thrombocythemia, polycythemia vera, and myeloid metaplasia and reveals the origins of dysregulation in JAK2V617F-mediated cell growth.
Materials and Methods
Expression Vectors. The murine JAK2 cDNA was cloned into the retroviral vectors MSCV-Neo and MSCV-GFP. The JAK2V617F mutation was generated by using site-directed mutagenesis (QuikChange-XL, Stratagene) and confirmed by full-length DNA sequencing. cells expressing the murine EpoR (BaF3 EpoR) (15) , and Ba͞F3 cells expressing murine TpoR (Ba͞F3 TpoR) (14) were grown in RPMI medium 1640 containing 10% FCS and 10% WEHI-3B cell supernatant as a source of IL-3 (WEHI media). These cells were transduced with retroviral supernatant containing either the MSCV-JAK2-Neo or MSCV-JAK2V617F-Neo vectors, respectively, and then selected in G418 (1 mg͞ ml). Ba͞F3 cells expressing human GCSFR (Ba͞F3 GCSFR) (16) and parental Ba͞F3 cells were transduced with retroviral supernatant containing either the MSCV-JAK2-GFP or MSCV-JAK2V617F-GFP vectors, respectively, and then sorted by f low cytometry to isolate GFP-positive cells. To assess for factor-independent growth, cells were washed three times in RPMI medium 1640 and cultured in the absence of Epo and IL-3 for 7 days. The number of viable cells was determined by trypan blue exclusion. 
Results
Expression of a Homodimeric Type I Cytokine Receptor Is Required for JAK2V617F-Mediated Transformation of Ba͞F3 Cells. We demonstrated that expression of TEL-JAK2 transforms the murine IL-3-dependent hematopoietic cell line Ba͞F3 to factorindependent growth (7) (Fig. 1a) . These properties are similar to those reported by our group and others for a number of mutant tyrosine kinases associated with hematopoietic malignancy that each confer factor-independent growth to Ba͞F3 cells, including BCR-ABL, TEL-PDGFRB, HIP1-PDGFRB, H4-PDGFRB, TEL-ABL, ZNF198-FGFR1, FIP1L1-PDGFRA, NPM-ALK, FLT3-ITD, FLT3 activation-loop mutations, and KIT activationloop mutations (2, (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) . In striking contrast, we observed that expression of JAK2V617F in Ba͞F3 cells did not confer IL-3-independent growth (Fig. 1a) . We next tested Ba͞F3 cells that express an ectopic EpoR, called Ba͞F3 EpoR cells. Importantly, JAK2V617F, but not wild-type JAK2, transformed Ba͞F3 EpoR cells to cytokine-independent growth (Fig. 1b) .
Cell-surface EpoR is a dimer in the absence of hormone (27) . Epo binding reorients the receptor extracellular and membranespanning domains, such that the two attached JAK2 kinases are brought into apposition, and one phosphorylates the critical tyrosine in the activation loop of the other kinase. Among Type I cytokine receptors, TpoR, GCSFR, and prolactin receptor (PrlR) are most closely related to EpoR, in that each forms a specifically oriented receptor homodimer after hormone binding, activates the associated JAK2, and, in turn, activates the STAT5 transcription factor (28) . Fig. 1 c and d shows that Ba͞F3 cells expressing TpoR or GCSFR are also transformed by JAK2V617F into cytokine-independent growth. In contrast, parental Ba͞F3 cells expressing only JAK2V617F, Ba͞F3 TpoR, or Ba͞F3 GCSFR cells expressing wild-type JAK2 remain untransformed. We made similar observations with Ba͞F3 cells expressing the PrlR and also with the IL-3-dependent 32D cell line expressing the EpoR, EpoR-TpoR, or EpoR-PrlR chimeras containing the extracellular domain of the EpoR and the membrane-spanning and cytosolic domains of the TpoR or PrlR, respectively (see Figs. 6 and 7, which are published as supporting information on the PNAS web site).
Constitutive Activation of JAK2V167F and Downstream STAT5 Require the Presence of a Homodimeric Type I Cytokine Receptor. The above findings suggest that, in contrast to all other known activating alleles of tyrosine kinases associated with hematopoietic malignancies, transformation to cytokine-independence by JAK2V617F requires its binding to the cytosolic domain of a cytokine receptor. Cytokinereceptor-triggered JAK2 transphosphorylation of the critical tyrosine residue in the activation loop requires the physical proximity of two JH1 kinase domains. In TEL-JAK2, the pointed domain of the ets transcription factor TEL directly dimerizes the JH1 domain and induces constitutive kinase activation (5, 7). Unlike TEL-JAK2, cytosolic JAK2V617F should not be able to form JAK2 homodimers. Because JAK2V617F retains domains JH3 to JH7 that mediate receptor association (8), we hypothesize that binding of JAK2V617F to a dimerized cytokine receptor is essential for cytokine-independent autotransphosphorylation that leads to kinase activation.
Indeed, Fig. 2a shows that expression of JAK2V617F in Ba͞F3 cells expressing EpoR, TpoR, or GCSFR results in a high level of JAK2 tyrosine phosphorylation in the absence of cytokine stimulation. In contrast, only background levels of JAK2 phosphorylation were observed after expression of JAK2V617F in parental Ba͞F3 cells or after expression of wild-type JAK2 in parental Ba͞F3 cells or Ba͞F3 cells expressing the EpoR, TpoR, or GCSFR.
After cytokine binding to Type I cytokine receptor and the activation of JAK2, JAK2 phosphorylates multiple tyrosines in the receptor cytosolic domain; these tyrosines serve as ''docking sites'' for the binding and subsequent tyrosine phosphorylation of multiple signal-transduction proteins, including STAT5. As expected, tyrosine phosphorylation of STAT5 in Ba͞F3 cells expressing EpoR, TpoR, or GCSFR and overexpressing wild-type JAK2 cannot be detected in the absence of cytokine stimulation. In contrast, there are high levels of tyrosine-phosphorylated STAT5 in Ba͞F3 EpoR, Ba͞F3 TpoR, and Ba͞F3 GCSFR cells expressing JAK2V617F in the absence of cytokine, whereas no tyrosinephosphorylated STAT5 is seen in parental Ba͞F3 cells expressing JAK2V617F (Fig. 2b) . Thus, cytokine-independent phosphorylation of both JAK2 and STAT5 in Ba͞F3 cells expressing JAK2V617F, like cytokine-independent cell proliferation, requires coexpression of a Type I cytokine receptor.
EpoR Association Is Essential for JAK2V617F-Mediated Transformation. JAK2 binds nascent EpoR and facilitates its surface expression. W282, a highly conserved amino acid in the EpoR cytosolic domain, is important for this functional interaction, because the W282A mutation disrupts JAK2-enhanced EpoR surface expression (8) . The W282R mutation in the EpoR also abolishes productive JAK2 binding and Epo-dependent JAK2 activation (29, 30) . Compared with Ba͞F3 cells expressing wild-type EpoR, Ba͞F3 cells expressing EpoRW282R exhibit no Epo-induced JAK2 phosphorylation, STAT5 phosphorylation, or EpoR phosphorylation (Fig. 3b-d, lanes 2 and 4) . In contrast to Ba͞F3 EpoR or 32D EpoR cells coexpressing JAK2V617F, Ba͞F3 or 32D cells coexpressing EpoRW282R and JAK2V617F do not undergo factor-independent proliferation ( Fig. 4 ; and see Fig. 8 , which is published as supporting information on the PNAS web site), and there is no cytokine-independent tyrosine phosphorylation of either JAK2V617F or STAT5, (Fig. 5, lane 6) . Thus, a functional interaction between JAK2 and EpoR is required for both Epo-dependent JAK2 activation and Epoindependent activation of JAK2V617F.
EpoR Provides Scaffolds for the Activation of STAT5 and for the
Maximal Cell Growth Mediated by JAK2V617F. The EpoR mutant EpoRF8 has all eight of its intracellular tyrosine residues mutated to phenylalanine (31) , and, like EpoRW282R, it cannot support Epo-dependent growth when expressed in Ba͞F3 cells (Fig. 3a) . When expressed in Ba͞F3 cells, EpoRF8 supports normal Epo-dependent activation of JAK2, but, as expected, there is no Epo-dependent tyrosine phosphorylation of the EpoR and greatly reduced STAT5 phosphorylation (Fig. 3) (31) . (The low level of STAT5 phosphorylation may result from binding of STAT5 to phosphotyrosines in JAK2 or may depend on other kinases that are activated by Epo stimulation.) Activation of other Epo-dependent signaling pathways, such as the PI-3 kinase͞AKT pathway is also greatly reduced in cells expressing EpoRF8, because these, too, depend on docking of SH2 domains of signaling proteins to phosphotyrosines in the EpoR cytosolic domain (32) . Figs. 4 and 8 show that Ba͞F3 or 32D cells coexpressing EpoRF8 and JAK2V617F undergo cytokineindependent proliferation at a much lower rate than do Ba͞F3 or 32D cells expressing wild-type EpoR and JAK2V617F, sug- gesting that the phosphotyrosine scaffold of EpoR plays a major role in transforming Ba͞F3 cells by JAK2V617F.
The supposition that tyrosine residues in the EpoR cytosolic domain are essential for maximal cytokine-independent signaling by JAK2V617F is supported by the experiment shown in Fig. 5  (lanes 7 and 8) . In Ba͞F3 EpoRF8 cells coexpressing JAK2V617F, cytokine-independent tyrosine phosphorylation of the JAK2V617F kinase occurs normally. However, there is a very low level of tyrosine phosphorylation of STAT5, presumably because essential tyrosines in the EpoR cytosolic domain are missing.
Discussion

JAK2 Plays a Central Role in the Signal Transduction by Homodimeric
Type I Cytokine Receptors Such as the EpoR. Without an intrinsic kinase domain, cytokine receptors rely on members of the JAK family of nonreceptor tyrosine kinases, such as JAK2, for their signaling. JAK2 is comprised of seven JAK homology (JH) domains, denoted JH1-JH7. Segments JH3-JH7, containing a FERM and SH2 domain, are essential for its binding to the membrane-proximal segment of the EpoR cytosolic domain (8) . Conserved regions in the EpoR cytosolic domain, including W282, are important for this interaction (30) . The C-terminal JH1 domain of JAK2 is a catalytically active tyrosine kinase, whereas the adjacent JH2 pseudokinase domain suppresses the basal kinase activity of the JH1 domain (33) .
Many Type I cytokine receptors, such as EpoR, exist as homodimers on the cell membrane (27) , and we presume that, in the absence of Epo, the appended JAK2 kinases are held in the ''off'' or nonphosphorylated state. Epo binding apparently changes the orientation of the two receptor extracellular domains, possibly causing a rotation of the receptor transmembrane domains that is transmitted to the membraneproximal cytosolic domains where JAK2 is bound (34) . Through unknown mechanisms, this conformational change displaces the JH2 inhibition of the JH1 kinase domain and juxtaposes the two appended JAK2 molecules in such an orientation that the activation loop of one JAK2 molecule can be phosphorylated by the other JAK2. Once these JAK2 become activated by reciprocal transphosphorylation, they phosphorylate several tyrosine residues in the EpoR intracellular domain, creating docking sites for SH2 domains of several signal-transduction proteins, such as STAT5, Shc, Grb2, and PI 3Ј kinase (35) . These events lead to the activation of multiple intracellular signaling pathways and specific gene inductions and repressions, resulting in the survival, proliferation, and differentiation of erythroid progenitors (35) .
Signal Transduction by JAK2V617F Requires a Cytokine Receptor as a
Scaffold. In one current structural model of JAK2, the activation loop of JH1 kinase domain is positioned such that substrate cannot bind. The JH2 pseudokinase domain inhibits the activation of the adjacent JH1 kinase domain by prohibiting the JH1 activation loop from flipping out of the substrate-binding pocket, so that the crucial tyrosine residues in the JAK2 JH1-activation loop cannot be reciprocally phosphorylated by adjacent JH1 kinases, and JAK2 remains inactive (36) . V617 in the JH2 domain is thought to be located on the JH1-JH2 interface, directly interacting with the activation loop of JH1 kinase domain.
The V617F mutation is thought to disrupt inhibition of JH1 by JH2, such that the activation loop of JH1 becomes extended and then phosphorylated by an adjacent JAK2V617F kinase. For this to happen, two JAK2 molecules must be physically close to each other. Unlike TEL-JAK2, which is a dimer and constitutively active, JAK2V617F is a monomeric cytosolic protein and is inactive in the absence of cognate cytokine receptors, as we show here.
Our most important result is that coexpression of a homodimeric Type I cytokine receptor is essential for cell transformation by the mutant JAK2V617F; EpoR, PrlR, TpoR, or GCSFR can suffice. The receptor cytosolic domain presumably binds JAK2V617F via its N-terminal FERM and SH2 domains (8). When JAK2V617F proteins bind to each of the EpoR subunit in a receptor homodimer, the weakened JH2 inhibition of the JH1 kinase domain allows one JAK2 kinase domain to phosphorylate the critical tyrosine on the other, even in the absence of cytokine binding. This result is supported by our finding that EpoRW282R is defective in both Epo-dependent activation of wild-type JAK2 and in cytokine-independent activation of JAK2V617F.
Cytosolic tyrosines in the EpoR cytosolic domain are dispensable for the tethering of JAK2 to the EpoR and Epodependent activation of JAK2 (Fig. 3b) ; however, cytosolic tyrosines are crucial for the maximal cell growth and activation of downstream signaling molecules induced by Epo. EpoRF8, lacking all cytosolic tyrosines, shows much reduced cytokineindependent growth conferred by JAK2V617F, indicating that EpoR not only serves as an anchorage for constitutive activation of JAK2V617F, but EpoR's ability to recruit downstream signaling molecules also plays a crucial role in the transforming capability of JAK2V617F. Cytosolic tyrosines in the EpoR cytosolic domain provide a scaffold that is essential for activation of downstream signal-transduction proteins, especially STAT5, by EpoR-attached JAK2V617F, as evidenced by our finding that EpoRF8 does not fully activate STAT5. These data also suggest that activation of STAT5 signaling is critical for JAK2V617F-mediated cytokine-independent proliferation and that inhibition of this signaling pathway may represent an important therapeutic strategy in JAK2V617F-positive myeloproliferative disorders.
Epo binding triggers conformational changes in the EpoR intracellular domains. This structural change may allow an appended JAK2V617F to assume a more favorable orientation for JAK2V617F transphosphorylation and͞or JAK2-mediated EpoR and͞or STAT5 phosphorylation, which may result in the observed Epo hypersensitivity (8) .
We do not know whether receptors or other proteins besides homodimeric Type I cytokine receptors can bind and activate JAK2V617F. The IL-3 receptor, a heterodimeric Type I receptor, is endogenously expressed in our parental Ba͞F3 and 32D cells, because these grow in the presence of IL-3. However, this level of expression of the IL-3 receptor is insufficient to support JAK2V617F-mediated transformation. It is important to assess other cytokine receptors for their ability to engage the trans- (Fig. 4). forming potential of JAK2V617F. Our observation that the ability of JAK2V617F to activate STAT5 and transform IL-3-dependent cells requires coexpression of homodimeric Type I cytokine receptors may provide insights into phenotypic pleiotropy of diseases mediated by this allele and into the natural selection of a single activating allele of JAK2V617F. Furthermore, the ability of the EpoR, TpoR, and GCSFR to bind and activate JAK2V617F provides a molecular basis for the prevalence of JAK2V617F in polycythemia vera, essential thrombocythemia, and myeloid metaplasia, diseases of myeloid-lineage cells that express these Type I cytokine receptors but not in lymphoid lineage cells that do not.
